论文部分内容阅读
原发性肾小球肾炎(PGN)大多为免疫复合物性肾炎(ICGN)。传统采用免疫抑制疗法,企图抑制IC形成,但疗效不理想。最近Camcron指出:“我认为未来肾炎治疗的主要希望不在于至今所主张的非特异性免疫抑制疗法,或控制介质,或……而是在于对失调免疫系统的特异性调节”。我们考虑到PGN病人有特异性免疫功能减低,因此自1984年起用免疫刺激剂—卡介苗(BCG)为主治疗PGN,取得较满意疗效。为进一步论证其疗效并探
Primary glomerulonephritis (PGN) are mostly immune complex nephritis (ICGN). Traditional immunosuppressive therapy, in an attempt to inhibit IC formation, but the effect is not satisfactory. Recently Camcron pointed out: “I think the main hope for the future treatment of nephritis lies not so far in the non-specific immunosuppressive therapy advocated, or control of media, or ... but rather the regulation of the immune system dysregulation”. We consider PGN patients with specific immune function decreased, so since 1984 with the immune stimulator - BCG mainly for the treatment of PGN, and achieved more satisfactory results. To further demonstrate its efficacy and exploration